ERBB2 and neoplasm: Tumour-to-liver, tumour-to-LDM and tumour-to-spleen ratios in mALNs with HER2 overexpression were 2.8 ± 1.3, 27.3 ± 28.0, and 6.7 ± 2.9, respectively.